These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19300870)

  • 1. Biomarkers for Alzheimer's disease trials--biomarkers for what? A discussion paper.
    Lovestone S; Thambisetty M
    J Nutr Health Aging; 2009 Apr; 13(4):334-6. PubMed ID: 19300870
    [No Abstract]   [Full Text] [Related]  

  • 2. Interpreting biomarker data in therapeutic trials.
    Aisen PS
    J Nutr Health Aging; 2009 Apr; 13(4):337-8. PubMed ID: 19300871
    [No Abstract]   [Full Text] [Related]  

  • 3. Alzheimer's disease biomarkers: their value in diagnosis and clinical trials.
    Small DH
    Front Biosci; 2002 Apr; 7():d986-8. PubMed ID: 11897567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.
    Knopman DS; Haeberlein SB; Carrillo MC; Hendrix JA; Kerchner G; Margolin R; Maruff P; Miller DS; Tong G; Tome MB; Murray ME; Nelson PT; Sano M; Mattsson N; Sultzer DL; Montine TJ; Jack CR; Kolb H; Petersen RC; Vemuri P; Canniere MZ; Schneider JA; Resnick SM; Romano G; van Harten AC; Wolk DA; Bain LJ; Siemers E
    Alzheimers Dement; 2018 Apr; 14(4):563-575. PubMed ID: 29653607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in clinical research on Alzheimer's disease: Leon Thal's legacy.
    Petersen RC
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S88-90. PubMed ID: 18632008
    [No Abstract]   [Full Text] [Related]  

  • 6. Biomarkers, assays, and therapies for Alzheimer disease.
    Beriault DR; Diamandis EP; Portelius E; Perret-Liaudet A; Salloway S
    Clin Chem; 2015 Jul; 61(7):903-8. PubMed ID: 26015517
    [No Abstract]   [Full Text] [Related]  

  • 7. Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies.
    Lyketsos CG; Szekely CA; Mielke MM; Rosenberg PB; Zandi PP
    Int Psychogeriatr; 2008 Oct; 20(5):871-89. PubMed ID: 18498669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of biomarkers in clinical trials for Alzheimer disease.
    Thal LJ; Kantarci K; Reiman EM; Klunk WE; Weiner MW; Zetterberg H; Galasko D; Praticò D; Griffin S; Schenk D; Siemers E
    Alzheimer Dis Assoc Disord; 2006; 20(1):6-15. PubMed ID: 16493230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease modifying trials in Alzheimer's disease: perspectives for the future.
    Vellas B; Coley N; Andrieu S
    J Alzheimers Dis; 2008 Oct; 15(2):289-301. PubMed ID: 18953115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical markers in Alzheimer's disease clinical trials.
    Zetterberg H; Mattsson N; Shaw LM; Blennow K
    Biomark Med; 2010 Feb; 4(1):91-8. PubMed ID: 20387305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials for early (pre-dementia) Alzheimer's disease: a case for mild cognitive impairment.
    Petersen RC
    J Nutr Health Aging; 2010 Apr; 14(4):304-5. PubMed ID: 20306001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Donohue MC; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw L; Thompson PM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jul; 11(7):865-84. PubMed ID: 26194320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research and standardization in Alzheimer's trials: reaching international consensus.
    Carrillo MC; Rowe CC; Szoeke C; Masters CL; Ames D; O'Meara T; Macaulay SL; Milner A; Ellis KA; Maruff P; Rainey-Smith SR; Martins RN; Bain LJ; Head RJ;
    Alzheimers Dement; 2013 Mar; 9(2):160-8. PubMed ID: 23266004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural imaging markers for therapeutic trials in Alzheimer's disease.
    Fox NC; Kennedy J
    J Nutr Health Aging; 2009 Apr; 13(4):350-2. PubMed ID: 19300877
    [No Abstract]   [Full Text] [Related]  

  • 15. Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective.
    Hampel H; Prvulovic D
    J Nutr Health Aging; 2012 Apr; 16(4):346-8. PubMed ID: 22499455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment.
    Visser PJ
    J Nutr Health Aging; 2009 Apr; 13(4):344-5. PubMed ID: 19300874
    [No Abstract]   [Full Text] [Related]  

  • 17. Methods for discerning disease-modifying effects in Alzheimer disease treatment trials.
    Kaye JA
    Arch Neurol; 2000 Mar; 57(3):312-4. PubMed ID: 10714654
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.
    Siemers E; DeMattos RB; May PC; Dean RA
    Biomark Med; 2010 Feb; 4(1):81-9. PubMed ID: 20387304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's disease clinical trials: changing the paradigm.
    Cummings JL
    Curr Psychiatry Rep; 2011 Dec; 13(6):437-42. PubMed ID: 22052382
    [No Abstract]   [Full Text] [Related]  

  • 20. Disease staging and milestones.
    Rabheru K
    Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S62-6. PubMed ID: 17469685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.